50 Ferncroft Rd,

Danvers,

MA,

US,

ZIP: 01923

Phone: (+1) 6174554188

The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Join 40+ speakers from the industry leaders in ophthalmic gene therapy such as: Adverum, REGENXBIO, Novartis, Janssen, Kriya, Nanoscope, IVERIC, GenSight, SparingVision, Atsena, AGTC, ViGeneron and many more as we discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.

This year an additional day to compliment the scientific program has been added. The NEW hotly anticipated post-conference delivery day will address the devices and technology involved in the delivery of these drugs. Additionally, our beloved pre-conference workshop day now has four thought-provoking workshops, covering topics that lend better to longer, more interactive discussions such as: non-viral modalities & US & EU regulatory considerations.

Join 150+ stake holders within the industry to overcome these challenges and get these drugs to the ophthalmic gene therapy patients who needs them as fast as possible.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Brochure https://go.evvnt.com/1139556-2?pid=1052
Tickets    https://go.evvnt.com/1139556-3?pid=1052

Prices:
Drug Developer Pricing - Full Access Pass (Conference + Workshop Day & Post Event Delivery Day) USD 4595.00
Drug Developer Pricing - Conference + Workshop Day OR Post Event Delivery Day USD 2797.00
Drug developer Pricing - Conference Only USD 2999.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Speakers: Sanghoon Kim, Project Engineer, Nanoscope Therapeutics, Josh Bartoe, Vice President , Ophthalmology Services, Northern Biomedical Research, Lauren Ayton, Associate Professor, & Head - Vision Optimisation, University of Melbourne, Lee Morris, Patient, Luxturna Patient (UK), Maen Obeidat, Executive Director - Therapeutics Area Head, Biomarker Development, Ophthalmology, Novartis, Markus Peters, Chief Executive Officer, Aevitas Therapeutics, Matthew Wood, Patient, Luxturna Patient (UK), Rachel Eclov, Gene Therapy Development Project Leader, Kriya Therapeutics, Samarendra Mohanty, Chief Scientific Officer & President, Nanoscope Therapeutics, Subrata Batabyal, Senior Technical Officer, Nanoscope Technologies, Viral Kansara, Vice President of Preclinical Development, Clearside Biomedical, Yoreh Barak, Director of Retina, Department of Ophthalmology, Everads Therapy, Nida Sen, Retina Global Clinical Development, Janssen, Diane Doughty, Director of Device Development, REGENXBIO, Catherine Cukras, Director of the Medical Retina Fellowship Program, NEI, Abraham Scaria, Chief Scientific Offier, IVERIC Bio, Aniz Girach, Chief Medical Officer, ProQR, Arun Upadhyay, Senior Vice Preisent of Research & Development, Ocugen, Ashwath Jayagopal, Chief Scientific Officer, Opus Genetics, Catherine O’Riordan, Head Translational Cluster, Genomics Unit, Sanofi, Catrina Santos, Europe Medical Director of Ophthalmology, Novartis, Rosario Fernandez-Godi, Director, Head of Retina Biology Lab, Intergalactic Therapeutics, Claire Gelfman, Chief Scientific Officer, Foundation Fighting Blindness, Daniel Chung, Chief Medical Officer, SparingVision, Erin O’Neil, Attending Physician, Children’s Hospital of Philadelphia, Francis Tukov, Director, Preclinical Safety Assessment, Novartis, Gayathri Ramaswamy, Vice President, Drug Discovery & Disease Biology, Intergalactic Therapeutics, Gerard Caelles, Chief Business Officer, Splice Bio, Hemant Khanna, Vice President of Preclinical Ocular Research, IVERIC Bio, Jake Ternent, Patient, Luxturna, Jasmina Kapetanovic, Clinician & Consultant Vitreo-Retinal Surgeon, University of Oxford, Linda Couto, Chief Scientific Officer, Atsena, Magali Taiel, Chief Medical Officer, GenSight Biologics, Richard Beckman, Chief Medical Officer, Adverum, Stephen Poor, Director of External Opportunities & Translational Biomarkers, Novartis, Steve Pakola, Chief Medical Officer, REGENXBIO, Stylianos Michalakis, Co-founder & Chief Scientific Advisor, ViGeneron, Theresa Heah, President & Chief Medical Officer, Kriya Ophthalmology, William Beltran, Director, Division of Experimental Retinal Therapies, University of Pennsylvania